+44 20 8123 2220
info@marketpublishers.com

Iduronate 2 Sulfatase - Drugs In Development, 2021

https://marketpublishers.com/r/IBA125397EC8EN.html
Date: June 2021
Pages: 75
Price: US$ 3,500.00 (Single User License)
ID: IBA125397EC8EN

Abstracts

Iduronate 2 Sulfatase - Drugs In Development, 2021

SUMMARY

According to the recently published report 'Iduronate 2 Sulfatase - Drugs In Development, 2021'; Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Iduronate 2-sulfatase (IDS) is a sulfatase enzyme associated with Hunter syndrome. Iduronate 2-sulfatase is required for the lysosomal degradation of heparan sulfate and dermatan sulfate. Mutations in this X-chromosome gene that result in enzymatic deficiency lead to Hunter syndrome.

The report 'Iduronate 2 Sulfatase - Drugs In Development, 2021' outlays comprehensive information on the Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 3 and 4 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas

+44 20 8123 2220
info@marketpublishers.com

Genetic Disorders and Central Nervous System which include indications Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) and Cognitive Impairment.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)

The report reviews Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics and enlists all their major and minor projects

The report assesses Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics

+44 20 8123 2220
info@marketpublishers.com

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

Featured News & Press Releases
May 14, 2021: REGENXBIO presents additional positive interim data from phase I/II trial of RGX-121 for the treatment of MPS II (Hunter Syndrome) at American Society of Gene and Cell Therapy's 24th Annual Meeting
Apr 14, 2021: Regenxbio announces dosing of first patient in cohort 3 of phase I/II trial of RGX-121 for the treatment of MPS II (Hunter syndrome)
Mar 23, 2021: JCR Pharmaceuticals announces approval of IZCARGO (pabinafusp alfa) for treatment of MPS II (Hunter syndrome) in Japan
Mar 11, 2021: Denali Therapeutics announces fast track designation granted by the U.S. FDA to ETV:IDS (DNL310) for the treatment of patients with Hunter syndrome (MPS II)
Mar 03, 2021: GC Green Cross to ship'Hunterase ICV' in Japan
Feb 16, 2021: JCR Pharmaceuticals presents research at WORLDSymposium 2021 showing potential benefits of JR-141 (pabinafusp alfa) in patients with MPS II (Hunter Syndrome)
Feb 12, 2021: Denali Therapeutics reports positive three-month data from phase 1/2 study with ETV:IDS (DNL310) in patients with hunter syndrome (MPS II)
Feb 10, 2021: JCR Pharmaceuticals receives FDA IND clearance to initiate global phase 3 clinical trial of JR-141 for Mucopolysaccharidosis Type II (Hunter Syndrome)
Feb 10, 2021: FDA grants fast track designation for JR-141 for the treatment of mucopolysaccharidosis type II (Hunter syndrome)
Feb 08, 2021: Homology Medicines announces first presentation of data with HMI-203 in vivo gene therapy development candidate for Hunter syndrome
Feb 08, 2021: Regenxbio presents additional positive interim data from Phase I/II Trial Of Rgx-121 For The Treatment Of MPS II (Hunter Syndrome) at 17th Annual Worldsymposium 2021
Feb 05, 2021: Denali Therapeutics to present new data on ETV:IDS (DNL310) for the potential treatment of Hunter syndrome at WORLDSymposium
Jan 27, 2021: JR-141 (Pabinafusp Alfa) for Hunter syndrome: Notice on the publication of the results of non-clinical trials in Molecular Therapy
Jan 22, 2021: Announcing marketing approval for Hunterase ICV Injection 15 mg, the world’s first enzyme replacement therapy for Mucopolysaccharidosis Type II (Hunter Syndrome) administered by ICV injection
Dec 23, 2020: JCR files Hunter Syndrome drug in Brazil
Appendix
Methodology
Coverage
Secondary Research
Primary Research

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Iduronate 2 Sulfatase - Drugs In Development, 2021
Product link: https://marketpublishers.com/r/IBA125397EC8EN.html
Price: US$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/IBA125397EC8EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970